A number of analysts have downgraded estimates for CVS Health (CVS) following the pharmacy benefit and retail pharmacy stalwart’s disappointing third-quarter 2024 results last week. The company’s adjusted earnings per share (EPS) of $1.09 plunged 50.7% year over year in the third quarter, reflecting continued utilization pressure and the unfavorable impact of the company's Medicare Advantage star ratings for the 2024 payment year within the Medicare product line.The company’s huge premium deficiency reserve ...